

**MEN/03/ZOF-CHF/001**

**Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction.  
(SMILE IV trial)**

**This study is currently recruiting patients**

**Sponsor:** Menarini International Operations Luxembourg S.A., Laboratori Guidotti S.p.A. and Istituto Lusofarmaco d'Italia S.p.A.

**Intervention:** Zofenopril 30 mg bid + ASA 100 mg  
Zofenopril 30 mg bid + ASA 325 mg  
Ramipril 5 mg bid + ASA 100 mg  
Ramipril 5 mg bid + ASA 325 mg

**Condition:** Systolic Left Ventricular Dysfunction after Acute Myocardial Infarction

This study is designed to demonstrate the cardiovascular benefit of the combination of Zofenopril + ASA in comparison to the combination of Ramipril + ASA on cardiovascular event rate in patients with post-MI systolic left ventricular dysfunction.

**Study type & design:** Randomised, double blind, controlled trial carried out in parallel groups

**Main criteria for inclusion:**

Acute myocardial infarction with clinical or echocardiographic evidence of systolic LV dysfunction.

**Main criteria for exclusion:**

Contraindications for ACE-i or ASA  
SBP < 90 mmHg